R&D channel feed

Hear­ing loss spe­cial­ists at Fre­quen­cy pin the blame for PhI­Ia flop on tri­al de­sign — but they could­n't stem a freefall in share price

5 years ago

'Part of re­cov­ery is aware­ness': Pan­dem­ic casts harsh spot­light on in­dus­try-wide lack of di­ver­si­ty in clin­i­cal tri­als

5 years ago
In Focus

No­var­tis’ $2B can­cer drug spurs ‘ground­break­ing’ PhI­II da­ta for prostate can­cer

5 years ago

Hop­ing to take drug R&D in­to the cloud, In­sight­ful Sci­ence snaps up da­ta man­age­ment out­fit Dot­mat­ics

5 years ago
Deals

Ex­clu­sive: Maze un­veils their $191M pipeline, tak­ing on Ver­tex and two long-sought con­di­tions

5 years ago

Roche cuts bait on late-stage study of Hunt­ing­ton's med tomin­ersen, an Io­n­is im­port with pri­or safe­ty flags

5 years ago

Take­da takes a swing at RNA small mol­e­cules with dis­cov­ery pact for mul­ti­ple po­ten­tial Evotec pro­grams

5 years ago
Deals

Those NDA plans Odonate had for mid-'21? They're be­ing scrapped — along with the en­tire biotech — in a sud­den im­plo­sion

5 years ago

Roche claims key win in the $12B ear­ly-stage check­point race

5 years ago
Pharma

As­traZeneca read­ies April EUA fil­ing with 79% vac­cine ef­fi­ca­cy, first glimpse of el­der­ly da­ta and 100% pro­tec­tion against se­vere dis­ease in US tri­al

5 years ago
Coronavirus

Bridge­Bio team clears a key hur­dle with their proof-of-con­cept da­ta for a rare ge­net­ic dis­ease. And they can thank the NIH for a quick suc­cess

5 years ago

Mer­ck breathes a sigh of re­lief as Keytru­da-Lenvi­ma com­bo aces con­fir­ma­to­ry study in en­dome­tri­al can­cer

5 years ago
Pharma

Jakafi failed the pri­ma­ry end­point in a Covid-19 study. But In­cyte is still go­ing to FDA with a com­pas­sion­ate use pitch

5 years ago
Coronavirus

Idera squelch­es any lin­ger­ing en­thu­si­asm as its lead TLR9 drug flunks PhI­II — bad­ly

5 years ago

Lit­tle Apel­lis is arm­ing it­self for a David and Go­liath bat­tle over a block­buster drug fran­chise

5 years ago

Lack of ear­ly ef­fi­ca­cy for Trans­late Bio's mR­NA-based cys­tic fi­bro­sis drug rais­es some big ques­tions

5 years ago

Eli Lil­ly's IL-23 in­hibitor mirik­izum­ab shows late-stage promise in ul­cer­a­tive col­i­tis — but Ab­b­Vie's Skyrizi looms

5 years ago
Pharma

No quick re­demp­tion for Glax­o­SmithK­line’s $4B al­liance with Mer­ck KGaA as bis­pe­cif­ic can­cer drug flunks a sec­ond tri­al

5 years ago

Sol­id Bio’s long, trou­bled slog through the clin­ic yields 'en­cour­ag­ing' ear­ly da­ta and no new safe­ty con­cerns. It's not win­ning over in­vestors yet

5 years ago
Cell/Gene Tx

Ru­bius chief lays out the first hu­man da­ta on their lead red cell drug in a come­back play. And the stock sky­rock­ets

5 years ago

On a roll, Re­gen­eron and Sanofi boast pos­i­tive PhI­II OS re­sults in 'no­to­ri­ous­ly' tough can­cer

5 years ago
Pharma

With hopes for an­ti­bod­ies wan­ing, the NIH will test No­var­tis part­ner's nov­el an­tivi­ral in hos­pi­tal­ized Covid-19 pa­tients

5 years ago
Coronavirus

Eli Lil­ly touts a 'con­stel­la­tion' of suc­cess­es with their PhII Alzheimer’s study — but dis­ap­point­ing fail­ures drag down shares

5 years ago
Bioregnum
Opinion

Gilead part­ner touts an ear­ly snap­shot of its HIV vac­cine ap­proach to a cure — but there's a long path ahead

5 years ago
First page Previous page 174175176177178179180 Next page Last page
A service from the Financial Times